Free Trial

Q1 Earnings Forecast for InnovAge Issued By William Blair

InnovAge logo with Medical background

Key Points

  • William Blair forecasts that InnovAge Holding Corp. will post earnings per share of $0.00 for Q1 2026, with a full-year consensus estimate of ($0.12) per share.
  • In its latest quarterly report, InnovAge exceeded earnings expectations with a reported loss of ($0.01) per share, along with revenues of $221.42 million, surpassing the anticipated $219.80 million.
  • Institutional investors have increased their holdings in InnovAge, with T. Rowe Price boosting its position by 4.4%, now owning over 5 million shares valued at approximately $15.7 million.
  • MarketBeat previews the top five stocks to own by November 1st.

InnovAge Holding Corp. (NASDAQ:INNV - Free Report) - Equities research analysts at William Blair issued their Q1 2026 EPS estimates for InnovAge in a research report issued on Wednesday, September 10th. William Blair analyst J. Haase expects that the company will post earnings per share of $0.00 for the quarter. The consensus estimate for InnovAge's current full-year earnings is ($0.12) per share.

InnovAge Price Performance

NASDAQ:INNV traded up $0.09 during mid-day trading on Thursday, hitting $5.07. 22,446 shares of the company's stock traded hands, compared to its average volume of 45,524. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.07 and a current ratio of 1.07. The firm's 50 day simple moving average is $3.82 and its 200 day simple moving average is $3.59. InnovAge has a 1 year low of $2.60 and a 1 year high of $6.69. The company has a market cap of $687.68 million, a PE ratio of -22.04 and a beta of 0.52.

InnovAge (NASDAQ:INNV - Get Free Report) last announced its quarterly earnings data on Tuesday, September 9th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.02) by $0.01. InnovAge had a negative net margin of 3.55% and a negative return on equity of 12.02%. The firm had revenue of $221.42 million during the quarter, compared to analysts' expectations of $219.80 million. InnovAge has set its FY 2026 guidance at EPS.

Hedge Funds Weigh In On InnovAge

Several hedge funds have recently added to or reduced their stakes in the business. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of InnovAge during the second quarter worth about $32,000. Squarepoint Ops LLC purchased a new stake in shares of InnovAge during the fourth quarter worth about $68,000. Bank of America Corp DE grew its holdings in shares of InnovAge by 42.4% during the fourth quarter. Bank of America Corp DE now owns 19,945 shares of the company's stock worth $78,000 after buying an additional 5,936 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of InnovAge during the second quarter worth about $110,000. Finally, Barclays PLC grew its holdings in shares of InnovAge by 13.6% during the fourth quarter. Barclays PLC now owns 29,099 shares of the company's stock worth $115,000 after buying an additional 3,485 shares in the last quarter. 12.26% of the stock is currently owned by hedge funds and other institutional investors.

About InnovAge

(Get Free Report)

InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management.

Featured Articles

Earnings History and Estimates for InnovAge (NASDAQ:INNV)

Should You Invest $1,000 in InnovAge Right Now?

Before you consider InnovAge, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InnovAge wasn't on the list.

While InnovAge currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.